Exane Derivatives’s PTC Therapeutics PTCT Stock Holding History

Exane Derivatives’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$481	Sell	12 -116	-91%	-$4.07K	﹤0.01%	573
2022 Q1	$4.78K	Sell	128 -34	-21%	-$1.31K	﹤0.01%	702
2021 Q4	$6.45K	Sell	162 -1,138	-88%	-$43.6K	﹤0.01%	610
2021 Q3	$48.4K	Sell	1,300 -282	-18%	-$11.6K	0.01%	617
2021 Q2	$68.7K	Hold	1,582	–	–	0.02%	591
2021 Q1	$74.9K	Hold	1,582	–	–	0.02%	462
2020 Q4	$96.5K	Sell	1,582 -2,009	-56%	-$118K	0.03%	399
2020 Q3	$168K	Buy	3,591 +1,900	+112%	+$93.5K	0.05%	224
2020 Q2	$85.8K	Hold	1,691	–	–	0.02%	314
2020 Q1	$75.4K	Sell	1,691 -251	-13%	-$12.6K	0.02%	317
2019 Q4	$100K	Buy	+1,942	New	+$82.5K	0.02%	314

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Exane Derivatives's PTCT Position: Q2 2022 in Review

Exane Derivatives reduced its PTC Therapeutics (PTCT) stake by 91% in Q2 2022, selling an estimated $4.07K and leaving 12 shares worth $481. The position accounts for ﹤0.01% of the portfolio, ranked #573.

Exane Derivatives first reported a position in PTCT in Q4 2019 and has held it in 11 quarters since. The position peaked at $168K in Q3 2020. 181 funds tracked by Wall St. Rank hold PTCT as of Q2 2022.

Exane Derivatives held 12 shares of PTC Therapeutics worth $481 as of Q2 2022.
Exane Derivatives sold 116 PTC Therapeutics shares in Q2 2022, an estimated $4.07K.
PTC Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #573 holding.
Exane Derivatives first reported a position in PTC Therapeutics in Q4 2019 and has held it in 11 quarters since.
Exane Derivatives's PTC Therapeutics position peaked at $168K in Q3 2020.
181 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.